Laurus Labs（540222）株式概要ローラス・ラボ社（Laurus Labs Limited）は、その子会社とともに、インド国内外において医薬品および医薬品原薬（API）の製造・販売を行っている。 詳細540222 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長3/6過去の実績4/6財務の健全性5/6配当金2/6報酬収益は年間18.76%増加すると予測されています 過去1年間で収益は148%増加しました リスク分析多額の負債を抱えている すべてのリスクチェックを見る540222 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹1.37k4.2% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0128b2016201920222025202620282031Revenue ₹128.2bEarnings ₹16.7bAdvancedSet Fair ValueView all narrativesLaurus Labs Limited 競合他社Alkem LaboratoriesSymbol: NSEI:ALKEMMarket cap: ₹639.4bAurobindo PharmaSymbol: NSEI:AUROPHARMAMarket cap: ₹818.4bGlenmark PharmaceuticalsSymbol: NSEI:GLENMARKMarket cap: ₹603.0bAbbott IndiaSymbol: BSE:500488Market cap: ₹551.4b価格と性能株価の高値、安値、推移の概要Laurus Labs過去の株価現在の株価₹1,368.9552週高値₹1,457.0052週安値₹640.95ベータ0.431ヶ月の変化3.15%3ヶ月変化44.54%1年変化106.35%3年間の変化275.52%5年間の変化122.54%IPOからの変化1,324.51%最新ニュースReported Earnings • Jun 13Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.1b (up 23% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • May 27Price target increased by 7.2% to ₹1,044Up from ₹974, the current price target is an average from 13 analysts. New target price is 24% below last closing price of ₹1,381. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₹20.53 for next year compared to ₹16.47 last year.Reported Earnings • May 05Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.7b (up 24% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • May 02Final dividend increased to ₹1.20Dividend of ₹1.20 is 50% higher than last year. Ex-date: 8th May 2026 Payment date: 30th May 2026 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (10% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 20% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 01Laurus Labs Limited Approves second Interim Dividend for Financial Year 2025-26, Payable on or After May 20, 2026Laurus Labs Limited announced that at the board meeting held on April 30, 2026, approved the payment of second interim dividend of INR 1.20/- (60%) per equity share of INR 2/- each, for the Financial Year 2025-26. Further, pursuant to Regulation 42 of the SEBI Listing Regulations, the company has fixed "May 08, 2026" as the "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2026.お知らせ • Apr 30Laurus Labs Limited, Annual General Meeting, Jul 02, 2026Laurus Labs Limited, Annual General Meeting, Jul 02, 2026.最新情報をもっと見るRecent updatesReported Earnings • Jun 13Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.1b (up 23% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • May 27Price target increased by 7.2% to ₹1,044Up from ₹974, the current price target is an average from 13 analysts. New target price is 24% below last closing price of ₹1,381. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₹20.53 for next year compared to ₹16.47 last year.Reported Earnings • May 05Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.7b (up 24% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Declared Dividend • May 02Final dividend increased to ₹1.20Dividend of ₹1.20 is 50% higher than last year. Ex-date: 8th May 2026 Payment date: 30th May 2026 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (10% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 20% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 01Laurus Labs Limited Approves second Interim Dividend for Financial Year 2025-26, Payable on or After May 20, 2026Laurus Labs Limited announced that at the board meeting held on April 30, 2026, approved the payment of second interim dividend of INR 1.20/- (60%) per equity share of INR 2/- each, for the Financial Year 2025-26. Further, pursuant to Regulation 42 of the SEBI Listing Regulations, the company has fixed "May 08, 2026" as the "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2026.お知らせ • Apr 30Laurus Labs Limited, Annual General Meeting, Jul 02, 2026Laurus Labs Limited, Annual General Meeting, Jul 02, 2026.お知らせ • Apr 10Laurus Labs Limited to Report Q4, 2026 Results on Apr 30, 2026Laurus Labs Limited announced that they will report Q4, 2026 results on Apr 30, 2026Reported Earnings • Jan 24Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.67 (up from ₹1.71 in 3Q 2025). Revenue: ₹17.8b (up 26% from 3Q 2025). Net income: ₹2.52b (up 173% from 3Q 2025). Profit margin: 14% (up from 6.5% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.お知らせ • Jan 09Laurus Labs Limited to Report Q3, 2026 Results on Jan 23, 2026Laurus Labs Limited announced that they will report Q3, 2026 results on Jan 23, 2026Declared Dividend • Oct 25First half dividend of ₹0.80 announcedShareholders will receive a dividend of ₹0.80. Ex-date: 31st October 2025 Payment date: 22nd November 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 23% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 86% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Price Target Changed • Oct 25Price target increased by 14% to ₹797Up from ₹701, the current price target is an average from 14 analysts. New target price is 14% below last closing price of ₹925. Stock is up 99% over the past year. The company is forecast to post earnings per share of ₹13.01 for next year compared to ₹6.65 last year.Reported Earnings • Oct 24Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹3.61 (up from ₹0.37 in 2Q 2025). Revenue: ₹16.5b (up 35% from 2Q 2025). Net income: ₹1.95b (up ₹1.75b from 2Q 2025). Profit margin: 12% (up from 1.6% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.お知らせ • Oct 09Laurus Labs Limited to Report Q2, 2026 Results on Oct 23, 2025Laurus Labs Limited announced that they will report Q2, 2026 results on Oct 23, 2025Price Target Changed • Jul 29Price target increased by 19% to ₹698Up from ₹586, the current price target is an average from 13 analysts. New target price is 23% below last closing price of ₹909. Stock is up 98% over the past year. The company is forecast to post earnings per share of ₹11.76 for next year compared to ₹6.65 last year.Reported Earnings • Jul 26First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: ₹3.02 (up from ₹0.23 in 1Q 2025). Revenue: ₹15.8b (up 32% from 1Q 2025). Net income: ₹1.63b (up ₹1.51b from 1Q 2025). Profit margin: 10% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 59%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.お知らせ • Jul 09Laurus Labs Limited to Report Q1, 2026 Results on Jul 25, 2025Laurus Labs Limited announced that they will report Q1, 2026 results on Jul 25, 2025Reported Earnings • Jun 08Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ₹6.65 (up from ₹2.98 in FY 2024). Revenue: ₹55.5b (up 10% from FY 2024). Net income: ₹3.58b (up 123% from FY 2024). Profit margin: 6.5% (up from 3.2% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.New Risk • May 20New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Paying a dividend despite having no free cash flows.お知らせ • May 15Laurus Labs Limited, Annual General Meeting, Jun 26, 2025Laurus Labs Limited, Annual General Meeting, Jun 26, 2025.Price Target Changed • Apr 26Price target increased by 8.3% to ₹565Up from ₹522, the current price target is an average from 14 analysts. New target price is 9.7% below last closing price of ₹625. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹10.60 for next year compared to ₹6.65 last year.Reported Earnings • Apr 25Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹6.65 (up from ₹2.98 in FY 2024). Revenue: ₹56.3b (up 12% from FY 2024). Net income: ₹3.58b (up 123% from FY 2024). Profit margin: 6.4% (up from 3.2% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.2%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Apr 24Laurus Labs Limited Approves Interim Dividend for Financial Year 2024 - 2025, Payable on or After May 20, 2025The Board of Directors of Laurus Labs Limited at their meeting held on April 24, 2025 approved for the payment of 2nd Interim Dividend of INR 0.80/- (40%) per equity share of INR 2/- each for the Financial Year 2024 - 2025. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "May 09, 2025" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2025.お知らせ • Apr 10Laurus Labs Limited to Report Q4, 2025 Results on Apr 24, 2025Laurus Labs Limited announced that they will report Q4, 2025 results on Apr 24, 2025Price Target Changed • Jan 27Price target increased by 14% to ₹512Up from ₹448, the current price target is an average from 14 analysts. New target price is approximately in line with last closing price of ₹535. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹5.85 for next year compared to ₹2.98 last year.Reported Earnings • Jan 25Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2025 results: EPS: ₹1.71 (up from ₹0.43 in 3Q 2024). Revenue: ₹14.2b (up 19% from 3Q 2024). Net income: ₹923.0m (up 299% from 3Q 2024). Profit margin: 6.5% (up from 1.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 06Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025Laurus Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025Declared Dividend • Oct 26First half dividend of ₹0.40 announcedDividend of ₹0.40 is the same as last year. Ex-date: 6th November 2024 Payment date: 23rd November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (33% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 281% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Oct 25Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: EPS: ₹0.37 (down from ₹0.69 in 2Q 2024). Revenue: ₹12.2b (flat on 2Q 2024). Net income: ₹198.4m (down 46% from 2Q 2024). Profit margin: 1.6% (down from 3.0% in 2Q 2024). Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 63%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.お知らせ • Oct 24Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025The Board of Directors of the Laurus Labs Limited at their meeting held on October 24, 2024 have approved for the payment of Interim Dividend of INR 0.40/- (20%) per equity share of INR 2/- each, for the Financial Year 2024- 2025. The Company has fixed November 06, 2024 as Record Date for determining the eligibility of the Shareholders. The Dividend will be paid within 30 days of declaration.お知らせ • Oct 17Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024Laurus Labs Limited announced that they will report Q2, 2025 results on Oct 24, 2024お知らせ • Oct 03Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent DirectorLaurus Labs Limited passed a resolution through Postal Ballot on October 3, 2024, appointment of Mr. Ramesh Subrahmanian as a Non-executive Independent Director of the Company. Approval of members for appointment of Mr. Ramesh Subrahmanian as an Independent Director, who was appointed as additional director in category of Independent Director on July 25, 2024. Appointment is effective from July 25, 2024, for a tenure of 5 years. The company confirm that Mr. Ramesh Subrahmanian meets the criteria for independence as required under Section 149(6) of the Companies Act, 2013 and the rules made thereunder and Regulation 16(1)(b) of the Listing Regulations and that he is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority. Mr. Ramesh Subrahmanian holds a bachelor's degree in Commerce from the University of Mumbai. He is also a certified Chartered Accountant from the Institute of Chartered Accountants in England & Wales. He has about 32 years of experience in pharmaceuticals, medical devices and speciality chemicals including immense years of experience with Sanofi and its predecessor companies (Aventis, HMR and Hoechst AG). He is also the founder and director of Alchemy Advisors, an advisory firm based in Singapore. Mr. Ramesh Subrahmanian is not related to any Director of the Company.Reported Earnings • Jul 26First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: ₹0.23 (down from ₹0.46 in 1Q 2024). Revenue: ₹12.0b (up 1.3% from 1Q 2024). Net income: ₹125.1m (down 50% from 1Q 2024). Profit margin: 1.0% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 89%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Jul 22Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024Laurus Labs Limited announced that they will report Q1, 2025 results on Jul 25, 2024お知らせ • Jul 12Laurus Labs Limited Announces Board AppointmentsLaurus Labs Limited announced at the AGM held on July 11, 2024, approved Appointment of Mr. Krishna Chaitanya Chava as Executive Director and Mr. Karnam Sekar (DIN 07400094) as Independent Director for a period of 5 years.Reported Earnings • Jun 20Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₹2.98 (down from ₹14.69 in FY 2023). Revenue: ₹50.4b (down 17% from FY 2023). Net income: ₹1.61b (down 80% from FY 2023). Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue. Post-clinical trial products Pre-registration: 40 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Additional Independent Director Karnam Sekar was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Declared Dividend • Apr 27Final dividend reduced to ₹0.40Dividend of ₹0.40 is 67% lower than last year. Ex-date: 8th May 2024 Payment date: 10th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (27% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 216% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Apr 27Laurus Labs Limited, Annual General Meeting, Jul 11, 2024Laurus Labs Limited, Annual General Meeting, Jul 11, 2024, at 15:00 Indian Standard Time.Reported Earnings • Apr 26Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₹2.98 (down from ₹14.69 in FY 2023). Revenue: ₹50.7b (down 16% from FY 2023). Net income: ₹1.61b (down 80% from FY 2023). Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Apr 26+ 1 more updateLaurus Labs Limited Approves Board ChangesLaurus Labs Limited announced that at its board meeting held on April 25, 2024, have resolved as follows (Outcome): the board has noted the completion of tenure of Dr. M. Venugopala Rao as chairman of the board and independent director of the company with effect from the close of business hours of May 17, 2024, who have served as Independent Director for 2 terms (1st term of 5 years and 2nd term of 2 years); In view of completion of tenure of Dr. M. Venugopala Rao as Chairman and Independent Director of the company with effect from close of business hours of May 17, 2024, Dr. Ravindranath Kancherla, independent director of the company is appointed as non-executive chairman of the board of directors of the company with effect from May 18, 2024. Dr. Ravindranath Kancherla is an independent director of the company since May 18, 2017 and until May 17, 2027; the board has approved the appointment of Mr. Karnam Sekar as an additional director in the capacity of independent director of the company with effect from April 25, 2024 to hold the office up to the conclusion of ensuing Annual General Meeting. Dr. Ravindranath Kancherla is an independent director of the company since May 18, 2017 and is now appointed as chairman of the board of directors of the company. Dr. Ravindranath Kancherla (69 Years) is a globally acclaimed expert in Surgical Gastroenterology and Laparoscopic Surgery. As the leader of Global Hospitals Group, he founded India's premier hospital exclusively focused on Gastroenterology and a state-of- the-art center for complex organ transplantations. His extensive surgical prowess includes liver, pancreatic, and bile duct resections, as well as advanced gastric and reconstructive coloproctology procedures. Renowned for his surgical acumen, Dr. Kancherla has played a role in advancing the field of minimally invasive surgery. Under his guidance, over 700 surgeons have been trained in laparoscopic procedures. Mr. Karnam Sekar (63 Years) is a business leader with more than four decades of rich experience in the Financial Services industry and with extensive knowledge of Corporate Finance, Treasury Management and Stressed Asset Management. He is currently serving on the board of Incred Financial services, Incred Prime Finance and UGRO Capital, Incred Holdings Ltd. Initially, He joined State Bank of India in 1983 as a Probationary Officer and rose to the level of Deputy Managing Director. He was selected as Managing Director of two Public Sector Banks viz., Dena Bank and Indian Overseas Bank, during very critical juncture of their history. He was the Chairman of the board of National Asset Reconstruction Company NARCL (May 2022-August 2023). Mr. Sekar holds a B.Sc (Ag), a CAIIB, and a Diploma in Management from AIMA. He has also earned diplomas in Financial Services and participated in leadership development programmes from institutions including IIM Calcutta, ISB Hyderabad, and Kellogg's Management School, Chicago.お知らせ • Apr 19Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024Laurus Labs Limited announced that they will report Q4, 2024 results on Apr 25, 2024Reported Earnings • Jan 25Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: ₹0.43 (down from ₹3.78 in 3Q 2023). Revenue: ₹12.0b (down 23% from 3Q 2023). Net income: ₹231.4m (down 89% from 3Q 2023). Profit margin: 1.9% (down from 13% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 79%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Jan 17Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024Laurus Labs Limited announced that they will report Q3, 2024 results on Jan 24, 2024Upcoming Dividend • Oct 26Upcoming dividend of ₹0.40 per share at 0.4% yieldEligible shareholders must have bought the stock before 02 November 2023. Payment date: 19 November 2023. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%).Price Target Changed • Oct 24Price target increased by 7.2% to ₹371Up from ₹346, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of ₹362. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹6.57 for next year compared to ₹14.69 last year.Reported Earnings • Oct 21Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: ₹0.69 (down from ₹4.33 in 2Q 2023). Revenue: ₹12.3b (down 22% from 2Q 2023). Net income: ₹369.5m (down 84% from 2Q 2023). Profit margin: 3.0% (down from 15% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Oct 21Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023Laurus Labs Limited announced that Board of Directors of the Company in their meeting held on October 20, 2023 have approved for the payment of interim dividend of INR 0.40/- (20%) per equity share of INR 2/- each, for the Financial Year 2023-24. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "October 30, 2023" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 09, 2023.お知らせ • Oct 14Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023Laurus Labs Limited announced that they will report Q2, 2024 results on Oct 20, 2023お知らせ • Sep 12Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million on September 11, 2023. Pursuant to the above acquisition, the stake of Laurus Labs in Laurus Bio shall reach to 87.58% on fully diluted basis (including outstanding ESOPs and the Share Warrants). Laurus Bio has revenue of INR 1,286.26 million, EBITDA of INR 369 million, total assets of INR 1,982.54 million, total equity of INR 481.64 million and net income of INR 141.9 million as of March 31, 2023. The Board of Directors of Laurus Labs have accorded its final approval for acquisition.Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹392, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹190 per share.New Risk • Jul 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.9% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Dividend is not well covered by cash flows (dividend per share is over 28x cash flows per share). Profit margins are more than 30% lower than last year (9.9% net profit margin).Reported Earnings • Jul 28First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)First quarter 2024 results: EPS: ₹0.46 (down from ₹4.68 in 1Q 2023). Revenue: ₹11.9b (down 23% from 1Q 2023). Net income: ₹248.5m (down 90% from 1Q 2023). Profit margin: 2.1% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Jun 24Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹14.69 (down from ₹15.42 in FY 2022). Revenue: ₹60.4b (up 22% from FY 2022). Net income: ₹7.90b (down 4.5% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 39 Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jun 01Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million on May 31, 2023. Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86%. In related transaction some of the Promoters and senior management of Laurus Labs would also invest approximately INR 40 million to purchase 0.54% stake. Transaction is expected to complete in approximately one month.Upcoming Dividend • May 03Upcoming dividend of ₹1.20 per share at 0.6% yieldEligible shareholders must have bought the stock before 10 May 2023. Payment date: 27 May 2023. Payout ratio is a comfortable 14% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).Price Target Changed • Apr 30Price target decreased by 11% to ₹382Down from ₹430, the current price target is an average from 10 analysts. New target price is 24% above last closing price of ₹308. Stock is down 47% over the past year. The company is forecast to post earnings per share of ₹12.56 for next year compared to ₹14.69 last year.Reported Earnings • Apr 28Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹14.69 (down from ₹15.42 in FY 2022). Revenue: ₹60.5b (up 23% from FY 2022). Net income: ₹7.90b (down 4.5% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Feb 01Price target decreased by 10% to ₹470Down from ₹523, the current price target is an average from 11 analysts. New target price is 40% above last closing price of ₹335. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹17.01 for next year compared to ₹15.42 last year.Reported Earnings • Jan 31Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: ₹3.78 (up from ₹2.87 in 3Q 2022). Revenue: ₹15.4b (up 50% from 3Q 2022). Net income: ₹2.03b (up 32% from 3Q 2022). Profit margin: 13% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.4%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 22Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023Laurus Labs Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Jan 30, 2023お知らせ • Nov 25Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private LimitedLaurus Labs Limited announced that it has entered into a security purchase agreement for the issuance of 740,000 equity shares at a price of INR 52.70 per share for gross proceeds INR 38,998,000 on November 23, 2022. The transaction will include participation from Ethan Energy India Private Limited.Price Target Changed • Nov 16Price target decreased to ₹561Down from ₹619, the current price target is an average from 11 analysts. New target price is 22% above last closing price of ₹462. Stock is down 4.7% over the past year. The company is forecast to post earnings per share of ₹19.27 for next year compared to ₹15.42 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Head of Quality & Executive Director Lakshmana Rao Chunduru was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Oct 28Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ₹68.3b to ₹63.9b. EPS estimate also fell from ₹22.34 per share to ₹19.27 per share. Net income forecast to grow 31% next year vs 32% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹619 to ₹561. Share price fell 8.8% to ₹445 over the past week.Upcoming Dividend • Oct 27Upcoming dividend of ₹0.80 per shareEligible shareholders must have bought the stock before 03 November 2022. Payment date: 20 November 2022. Payout ratio is a comfortable 12% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).Price Target Changed • Oct 26Price target decreased to ₹574Down from ₹619, the current price target is an average from 11 analysts. New target price is 27% above last closing price of ₹453. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₹19.34 for next year compared to ₹15.42 last year.お知らせ • Oct 22Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022The board of directors of Laurus Labs Limited in their meeting held on October 21, 2022 have approved for the payment of interim dividend of INR 0.80 (40%) per equity share of INR 2 each, for the financial year 2022-2023. The company has fixed November 04, 2022 as record date for determining the eligibility of the Shareholders. The dividend amount will be paid on or after November 15, 2022.Reported Earnings • Oct 22Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹4.33 (up from ₹3.76 in 2Q 2022). Revenue: ₹15.8b (up 31% from 2Q 2022). Net income: ₹2.33b (up 15% from 2Q 2022). Profit margin: 15% (down from 17% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 14Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022Laurus Labs Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Oct 21, 2022Reported Earnings • Jul 28First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: EPS: ₹4.68 (up from ₹4.50 in 1Q 2022). Revenue: ₹15.4b (up 20% from 1Q 2022). Net income: ₹2.51b (up 4.1% from 1Q 2022). Profit margin: 16% (down from 19% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 8.4%. Over the next year, revenue is forecast to grow 33%, compared to a 12% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 20Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022Laurus Labs Limited announced that they will report Q1, 2023 results on Jul 27, 2022Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹444, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹298 per share.Reported Earnings • Jun 09Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: EPS: ₹15.42 (down from ₹18.36 in FY 2021). Revenue: ₹49.4b (up 2.5% from FY 2021). Net income: ₹8.28b (down 16% from FY 2021). Profit margin: 17% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 34 Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 34%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • May 03Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 10 May 2022. Payment date: 28 May 2022. Payout ratio is a comfortable 13% but the company is paying out more than the cash it is generating. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%).Reported Earnings • Apr 29Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: EPS: ₹15.42 (down from ₹18.36 in FY 2021). Revenue: ₹49.5b (up 2.9% from FY 2021). Net income: ₹8.28b (down 16% from FY 2021). Profit margin: 17% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 23%, compared to a 12% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 94% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Executive Director Lakshmana Rao Chunduru was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 22Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022Laurus Labs Limited announced that they will report Q4, 2022 results on Apr 28, 2022Major Estimate Revision • Feb 03Consensus revenue estimates fall by 14%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from ₹55.7b to ₹47.9b. EPS estimate fell from ₹19.51 to ₹15.40 per share. Net income forecast to grow 18% next year vs 21% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹607 to ₹563. Share price rose 11% to ₹526 over the past week.Price Target Changed • Feb 02Price target decreased to ₹563Down from ₹607, the current price target is an average from 11 analysts. New target price is 7.1% above last closing price of ₹526. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹15.40 for next year compared to ₹18.36 last year.Reported Earnings • Jan 28Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹2.87 (down from ₹5.09 in 3Q 2021). Revenue: ₹10.3b (down 20% from 3Q 2021). Net income: ₹1.54b (down 44% from 3Q 2021). Profit margin: 15% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 37%. Over the next year, revenue is forecast to grow 30%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Nov 10Upcoming dividend of ₹0.80 per shareEligible shareholders must have bought the stock before 17 November 2021. Payment date: 27 November 2021. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.8%).Reported Earnings • Nov 01Second quarter 2022 earnings released: EPS ₹3.76 (vs ₹4.53 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹12.0b (up 5.7% from 2Q 2021). Net income: ₹2.02b (down 17% from 2Q 2021). Profit margin: 17% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 22Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹537, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 696% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹557 per share.Recent Insider Transactions • Sep 22Insider recently sold ₹7.9m worth of stockOn the 17th of September, Vijaya Suryadevara sold around 12k shares on-market at roughly ₹658 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹99m. Insiders have been net sellers, collectively disposing of ₹970m more than they bought in the last 12 months.Recent Insider Transactions • Sep 11Insider recently sold ₹3.2m worth of stockOn the 6th of September, Sreelakshmi Gogireddy sold around 5k shares on-market at roughly ₹649 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹99m. Insiders have been net sellers, collectively disposing of ₹959m more than they bought in the last 12 months.Recent Insider Transactions • Sep 04Insider recently sold ₹3.6m worth of stockOn the 31st of August, Yalamanchili Rama sold around 6k shares on-market at roughly ₹657 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹250m. Insiders have been net sellers, collectively disposing of ₹858m more than they bought in the last 12 months.Recent Insider Transactions • Aug 13Insider recently sold ₹1.0m worth of stockOn the 9th of August, Madhuveer Yadavalli sold around 1k shares on-market at roughly ₹701 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹250m. Insiders have been net sellers, collectively disposing of ₹788m more than they bought in the last 12 months.Price Target Changed • Aug 04Price target increased to ₹561Up from ₹512, the current price target is an average from 8 analysts. New target price is 13% below last closing price of ₹646. Stock is up 214% over the past year.Reported Earnings • Jul 30First quarter 2022 earnings released: EPS ₹4.50 (vs ₹3.21 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹12.8b (up 32% from 1Q 2021). Net income: ₹2.41b (up 41% from 1Q 2021). Profit margin: 19% (up from 18% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year whereas the company’s share price has increased by 90% per year.Price Target Changed • Jul 12Price target increased to ₹506Up from ₹470, the current price target is an average from 8 analysts. New target price is 25% below last closing price of ₹677. Stock is up 443% over the past year.お知らせ • Jul 03Laurus Labs Limited Receives the License to Manufacture and Market 2-Deoxy-D-Glucose (2DG) in IndiaLaurus Labs Limited announces that it has received the license from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country. Laurus Labs has already applied with CDSCO for emergency use authorization (EUA) for 2DG.Reported Earnings • Jun 24Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹48.1b (up 70% from FY 2020). Net income: ₹9.84b (up 285% from FY 2020). Profit margin: 20% (up from 9.0% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Pre-registration: 18 Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 90% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • May 23Insider recently bought ₹4.0m worth of stockOn the 21st of May, Satish Adewar bought around 8k shares on-market at roughly ₹486 per share. In the last 3 months, they made an even bigger purchase worth ₹6.4m. Insiders have collectively bought ₹92m more in shares than they have sold in the last 12 months.Recent Insider Transactions • May 07Insider recently sold ₹35m worth of stockOn the 3rd of May, K. Rao sold around 76k shares on-market at roughly ₹466 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹104m more than they sold in the last 12 months.Major Estimate Revision • May 06Consensus EPS estimates increase to ₹21.57The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₹53.6b to ₹57.9b. EPS estimate increased from ₹19.60 to ₹21.57 per share. Net income forecast to grow 18% next year vs 20% growth forecast for Pharmaceuticals industry in India. Consensus price target up from ₹399 to ₹457. Share price rose 5.1% to ₹482 over the past week.Price Target Changed • May 05Price target increased to ₹430Up from ₹396, the current price target is an average from 7 analysts. New target price is 13% below last closing price of ₹491. Stock is up 386% over the past year.Upcoming Dividend • May 04Upcoming dividend of ₹0.80 per shareEligible shareholders must have bought the stock before 11 May 2021. Payment date: 29 May 2021. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.7%).Reported Earnings • May 01Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹48.4b (up 71% from FY 2020). Net income: ₹9.84b (up 285% from FY 2020). Profit margin: 20% (up from 9.0% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 65% per year, which means it is significantly lagging earnings growth.株主還元540222IN PharmaceuticalsIN 市場7D-1.2%-0.03%2.2%1Y106.4%7.7%-0.5%株主還元を見る業界別リターン: 540222過去 1 年間で7.7 % の収益を上げたIndian Pharmaceuticals業界を上回りました。リターン対市場: 540222過去 1 年間で-0.5 % の収益を上げたIndian市場を上回りました。価格変動Is 540222's price volatile compared to industry and market?540222 volatility540222 Average Weekly Movement4.3%Pharmaceuticals Industry Average Movement7.2%Market Average Movement7.1%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%安定した株価: 540222 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 540222の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20057,059Satyanarayana Chavawww.lauruslabs.comLaurus Labs Limitedは、その子会社とともに、インド国内外において医薬品および医薬品原薬の製造・販売を行っている。同社は、抗レトロウイルス（ARV）、抗糖尿病、循環器、抗喘息、眼科、腫瘍、消化器、C型肝炎の治療領域向けの高度中間体ジェネリック医薬品原薬を提供している。また、ARV、抗糖尿病、循環器、PPIの経口固形製剤も提供している。さらに、受託開発・製造組織サービスや、栄養補助食品、栄養補助食品、代替食品タンパク質、化粧品に使用されるバイオテクノロジーサービスも提供している。さらに、産業バイオテクノロジー向けの新規酵素ソリューション、バイオ医薬品向けの動物由来の組み換えタンパク質や酵素の開発、医薬品分野のビジネスサポートサービスも提供している。ローラス・ラボ社は2005年に設立され、インドのハイデラバードに拠点を置く。もっと見るLaurus Labs Limited 基礎のまとめLaurus Labs の収益と売上を時価総額と比較するとどうか。540222 基礎統計学時価総額₹739.50b収益（TTM）₹8.89b売上高(TTM)₹68.13b83.2xPER（株価収益率10.9xP/Sレシオ540222 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計540222 損益計算書（TTM）収益₹68.13b売上原価₹28.30b売上総利益₹39.83bその他の費用₹30.95b収益₹8.89b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）16.46グロス・マージン58.47%純利益率13.05%有利子負債／自己資本比率44.1%540222 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.2%現在の配当利回り12%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 18:10終値2026/06/17 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Laurus Labs Limited 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedAshwin MehtaAmbit Capitalnull nullAntique Stockbroking Ltd.19 その他のアナリストを表示
Reported Earnings • Jun 13Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.1b (up 23% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • May 27Price target increased by 7.2% to ₹1,044Up from ₹974, the current price target is an average from 13 analysts. New target price is 24% below last closing price of ₹1,381. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₹20.53 for next year compared to ₹16.47 last year.
Reported Earnings • May 05Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.7b (up 24% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • May 02Final dividend increased to ₹1.20Dividend of ₹1.20 is 50% higher than last year. Ex-date: 8th May 2026 Payment date: 30th May 2026 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (10% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 20% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 01Laurus Labs Limited Approves second Interim Dividend for Financial Year 2025-26, Payable on or After May 20, 2026Laurus Labs Limited announced that at the board meeting held on April 30, 2026, approved the payment of second interim dividend of INR 1.20/- (60%) per equity share of INR 2/- each, for the Financial Year 2025-26. Further, pursuant to Regulation 42 of the SEBI Listing Regulations, the company has fixed "May 08, 2026" as the "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2026.
お知らせ • Apr 30Laurus Labs Limited, Annual General Meeting, Jul 02, 2026Laurus Labs Limited, Annual General Meeting, Jul 02, 2026.
Reported Earnings • Jun 13Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.1b (up 23% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • May 27Price target increased by 7.2% to ₹1,044Up from ₹974, the current price target is an average from 13 analysts. New target price is 24% below last closing price of ₹1,381. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₹20.53 for next year compared to ₹16.47 last year.
Reported Earnings • May 05Full year 2026 earnings: EPS exceeds analyst expectationsFull year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.7b (up 24% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Declared Dividend • May 02Final dividend increased to ₹1.20Dividend of ₹1.20 is 50% higher than last year. Ex-date: 8th May 2026 Payment date: 30th May 2026 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (10% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 20% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 01Laurus Labs Limited Approves second Interim Dividend for Financial Year 2025-26, Payable on or After May 20, 2026Laurus Labs Limited announced that at the board meeting held on April 30, 2026, approved the payment of second interim dividend of INR 1.20/- (60%) per equity share of INR 2/- each, for the Financial Year 2025-26. Further, pursuant to Regulation 42 of the SEBI Listing Regulations, the company has fixed "May 08, 2026" as the "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2026.
お知らせ • Apr 30Laurus Labs Limited, Annual General Meeting, Jul 02, 2026Laurus Labs Limited, Annual General Meeting, Jul 02, 2026.
お知らせ • Apr 10Laurus Labs Limited to Report Q4, 2026 Results on Apr 30, 2026Laurus Labs Limited announced that they will report Q4, 2026 results on Apr 30, 2026
Reported Earnings • Jan 24Third quarter 2026 earnings: EPS and revenues exceed analyst expectationsThird quarter 2026 results: EPS: ₹4.67 (up from ₹1.71 in 3Q 2025). Revenue: ₹17.8b (up 26% from 3Q 2025). Net income: ₹2.52b (up 173% from 3Q 2025). Profit margin: 14% (up from 6.5% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
お知らせ • Jan 09Laurus Labs Limited to Report Q3, 2026 Results on Jan 23, 2026Laurus Labs Limited announced that they will report Q3, 2026 results on Jan 23, 2026
Declared Dividend • Oct 25First half dividend of ₹0.80 announcedShareholders will receive a dividend of ₹0.80. Ex-date: 31st October 2025 Payment date: 22nd November 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 23% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 86% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Price Target Changed • Oct 25Price target increased by 14% to ₹797Up from ₹701, the current price target is an average from 14 analysts. New target price is 14% below last closing price of ₹925. Stock is up 99% over the past year. The company is forecast to post earnings per share of ₹13.01 for next year compared to ₹6.65 last year.
Reported Earnings • Oct 24Second quarter 2026 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2026 results: EPS: ₹3.61 (up from ₹0.37 in 2Q 2025). Revenue: ₹16.5b (up 35% from 2Q 2025). Net income: ₹1.95b (up ₹1.75b from 2Q 2025). Profit margin: 12% (up from 1.6% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
お知らせ • Oct 09Laurus Labs Limited to Report Q2, 2026 Results on Oct 23, 2025Laurus Labs Limited announced that they will report Q2, 2026 results on Oct 23, 2025
Price Target Changed • Jul 29Price target increased by 19% to ₹698Up from ₹586, the current price target is an average from 13 analysts. New target price is 23% below last closing price of ₹909. Stock is up 98% over the past year. The company is forecast to post earnings per share of ₹11.76 for next year compared to ₹6.65 last year.
Reported Earnings • Jul 26First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: ₹3.02 (up from ₹0.23 in 1Q 2025). Revenue: ₹15.8b (up 32% from 1Q 2025). Net income: ₹1.63b (up ₹1.51b from 1Q 2025). Profit margin: 10% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 59%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings.
お知らせ • Jul 09Laurus Labs Limited to Report Q1, 2026 Results on Jul 25, 2025Laurus Labs Limited announced that they will report Q1, 2026 results on Jul 25, 2025
Reported Earnings • Jun 08Full year 2025 earnings: EPS and revenues exceed analyst expectationsFull year 2025 results: EPS: ₹6.65 (up from ₹2.98 in FY 2024). Revenue: ₹55.5b (up 10% from FY 2024). Net income: ₹3.58b (up 123% from FY 2024). Profit margin: 6.5% (up from 3.2% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
New Risk • May 20New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Paying a dividend despite having no free cash flows.
お知らせ • May 15Laurus Labs Limited, Annual General Meeting, Jun 26, 2025Laurus Labs Limited, Annual General Meeting, Jun 26, 2025.
Price Target Changed • Apr 26Price target increased by 8.3% to ₹565Up from ₹522, the current price target is an average from 14 analysts. New target price is 9.7% below last closing price of ₹625. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹10.60 for next year compared to ₹6.65 last year.
Reported Earnings • Apr 25Full year 2025 earnings: EPS exceeds analyst expectationsFull year 2025 results: EPS: ₹6.65 (up from ₹2.98 in FY 2024). Revenue: ₹56.3b (up 12% from FY 2024). Net income: ₹3.58b (up 123% from FY 2024). Profit margin: 6.4% (up from 3.2% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.2%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Apr 24Laurus Labs Limited Approves Interim Dividend for Financial Year 2024 - 2025, Payable on or After May 20, 2025The Board of Directors of Laurus Labs Limited at their meeting held on April 24, 2025 approved for the payment of 2nd Interim Dividend of INR 0.80/- (40%) per equity share of INR 2/- each for the Financial Year 2024 - 2025. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "May 09, 2025" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2025.
お知らせ • Apr 10Laurus Labs Limited to Report Q4, 2025 Results on Apr 24, 2025Laurus Labs Limited announced that they will report Q4, 2025 results on Apr 24, 2025
Price Target Changed • Jan 27Price target increased by 14% to ₹512Up from ₹448, the current price target is an average from 14 analysts. New target price is approximately in line with last closing price of ₹535. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹5.85 for next year compared to ₹2.98 last year.
Reported Earnings • Jan 25Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2025 results: EPS: ₹1.71 (up from ₹0.43 in 3Q 2024). Revenue: ₹14.2b (up 19% from 3Q 2024). Net income: ₹923.0m (up 299% from 3Q 2024). Profit margin: 6.5% (up from 1.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 06Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025Laurus Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025
Declared Dividend • Oct 26First half dividend of ₹0.40 announcedDividend of ₹0.40 is the same as last year. Ex-date: 6th November 2024 Payment date: 23rd November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (33% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 281% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Oct 25Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: EPS: ₹0.37 (down from ₹0.69 in 2Q 2024). Revenue: ₹12.2b (flat on 2Q 2024). Net income: ₹198.4m (down 46% from 2Q 2024). Profit margin: 1.6% (down from 3.0% in 2Q 2024). Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 63%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 24Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025The Board of Directors of the Laurus Labs Limited at their meeting held on October 24, 2024 have approved for the payment of Interim Dividend of INR 0.40/- (20%) per equity share of INR 2/- each, for the Financial Year 2024- 2025. The Company has fixed November 06, 2024 as Record Date for determining the eligibility of the Shareholders. The Dividend will be paid within 30 days of declaration.
お知らせ • Oct 17Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024Laurus Labs Limited announced that they will report Q2, 2025 results on Oct 24, 2024
お知らせ • Oct 03Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent DirectorLaurus Labs Limited passed a resolution through Postal Ballot on October 3, 2024, appointment of Mr. Ramesh Subrahmanian as a Non-executive Independent Director of the Company. Approval of members for appointment of Mr. Ramesh Subrahmanian as an Independent Director, who was appointed as additional director in category of Independent Director on July 25, 2024. Appointment is effective from July 25, 2024, for a tenure of 5 years. The company confirm that Mr. Ramesh Subrahmanian meets the criteria for independence as required under Section 149(6) of the Companies Act, 2013 and the rules made thereunder and Regulation 16(1)(b) of the Listing Regulations and that he is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority. Mr. Ramesh Subrahmanian holds a bachelor's degree in Commerce from the University of Mumbai. He is also a certified Chartered Accountant from the Institute of Chartered Accountants in England & Wales. He has about 32 years of experience in pharmaceuticals, medical devices and speciality chemicals including immense years of experience with Sanofi and its predecessor companies (Aventis, HMR and Hoechst AG). He is also the founder and director of Alchemy Advisors, an advisory firm based in Singapore. Mr. Ramesh Subrahmanian is not related to any Director of the Company.
Reported Earnings • Jul 26First quarter 2025 earnings: EPS and revenues miss analyst expectationsFirst quarter 2025 results: EPS: ₹0.23 (down from ₹0.46 in 1Q 2024). Revenue: ₹12.0b (up 1.3% from 1Q 2024). Net income: ₹125.1m (down 50% from 1Q 2024). Profit margin: 1.0% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 89%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 22Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024Laurus Labs Limited announced that they will report Q1, 2025 results on Jul 25, 2024
お知らせ • Jul 12Laurus Labs Limited Announces Board AppointmentsLaurus Labs Limited announced at the AGM held on July 11, 2024, approved Appointment of Mr. Krishna Chaitanya Chava as Executive Director and Mr. Karnam Sekar (DIN 07400094) as Independent Director for a period of 5 years.
Reported Earnings • Jun 20Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₹2.98 (down from ₹14.69 in FY 2023). Revenue: ₹50.4b (down 17% from FY 2023). Net income: ₹1.61b (down 80% from FY 2023). Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue. Post-clinical trial products Pre-registration: 40 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Additional Independent Director Karnam Sekar was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Declared Dividend • Apr 27Final dividend reduced to ₹0.40Dividend of ₹0.40 is 67% lower than last year. Ex-date: 8th May 2024 Payment date: 10th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (27% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 216% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Apr 27Laurus Labs Limited, Annual General Meeting, Jul 11, 2024Laurus Labs Limited, Annual General Meeting, Jul 11, 2024, at 15:00 Indian Standard Time.
Reported Earnings • Apr 26Full year 2024 earnings: EPS misses analyst expectationsFull year 2024 results: EPS: ₹2.98 (down from ₹14.69 in FY 2023). Revenue: ₹50.7b (down 16% from FY 2023). Net income: ₹1.61b (down 80% from FY 2023). Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 26+ 1 more updateLaurus Labs Limited Approves Board ChangesLaurus Labs Limited announced that at its board meeting held on April 25, 2024, have resolved as follows (Outcome): the board has noted the completion of tenure of Dr. M. Venugopala Rao as chairman of the board and independent director of the company with effect from the close of business hours of May 17, 2024, who have served as Independent Director for 2 terms (1st term of 5 years and 2nd term of 2 years); In view of completion of tenure of Dr. M. Venugopala Rao as Chairman and Independent Director of the company with effect from close of business hours of May 17, 2024, Dr. Ravindranath Kancherla, independent director of the company is appointed as non-executive chairman of the board of directors of the company with effect from May 18, 2024. Dr. Ravindranath Kancherla is an independent director of the company since May 18, 2017 and until May 17, 2027; the board has approved the appointment of Mr. Karnam Sekar as an additional director in the capacity of independent director of the company with effect from April 25, 2024 to hold the office up to the conclusion of ensuing Annual General Meeting. Dr. Ravindranath Kancherla is an independent director of the company since May 18, 2017 and is now appointed as chairman of the board of directors of the company. Dr. Ravindranath Kancherla (69 Years) is a globally acclaimed expert in Surgical Gastroenterology and Laparoscopic Surgery. As the leader of Global Hospitals Group, he founded India's premier hospital exclusively focused on Gastroenterology and a state-of- the-art center for complex organ transplantations. His extensive surgical prowess includes liver, pancreatic, and bile duct resections, as well as advanced gastric and reconstructive coloproctology procedures. Renowned for his surgical acumen, Dr. Kancherla has played a role in advancing the field of minimally invasive surgery. Under his guidance, over 700 surgeons have been trained in laparoscopic procedures. Mr. Karnam Sekar (63 Years) is a business leader with more than four decades of rich experience in the Financial Services industry and with extensive knowledge of Corporate Finance, Treasury Management and Stressed Asset Management. He is currently serving on the board of Incred Financial services, Incred Prime Finance and UGRO Capital, Incred Holdings Ltd. Initially, He joined State Bank of India in 1983 as a Probationary Officer and rose to the level of Deputy Managing Director. He was selected as Managing Director of two Public Sector Banks viz., Dena Bank and Indian Overseas Bank, during very critical juncture of their history. He was the Chairman of the board of National Asset Reconstruction Company NARCL (May 2022-August 2023). Mr. Sekar holds a B.Sc (Ag), a CAIIB, and a Diploma in Management from AIMA. He has also earned diplomas in Financial Services and participated in leadership development programmes from institutions including IIM Calcutta, ISB Hyderabad, and Kellogg's Management School, Chicago.
お知らせ • Apr 19Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024Laurus Labs Limited announced that they will report Q4, 2024 results on Apr 25, 2024
Reported Earnings • Jan 25Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: EPS: ₹0.43 (down from ₹3.78 in 3Q 2023). Revenue: ₹12.0b (down 23% from 3Q 2023). Net income: ₹231.4m (down 89% from 3Q 2023). Profit margin: 1.9% (down from 13% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 79%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Jan 17Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024Laurus Labs Limited announced that they will report Q3, 2024 results on Jan 24, 2024
Upcoming Dividend • Oct 26Upcoming dividend of ₹0.40 per share at 0.4% yieldEligible shareholders must have bought the stock before 02 November 2023. Payment date: 19 November 2023. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%).
Price Target Changed • Oct 24Price target increased by 7.2% to ₹371Up from ₹346, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of ₹362. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹6.57 for next year compared to ₹14.69 last year.
Reported Earnings • Oct 21Second quarter 2024 earnings: EPS and revenues miss analyst expectationsSecond quarter 2024 results: EPS: ₹0.69 (down from ₹4.33 in 2Q 2023). Revenue: ₹12.3b (down 22% from 2Q 2023). Net income: ₹369.5m (down 84% from 2Q 2023). Profit margin: 3.0% (down from 15% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Oct 21Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023Laurus Labs Limited announced that Board of Directors of the Company in their meeting held on October 20, 2023 have approved for the payment of interim dividend of INR 0.40/- (20%) per equity share of INR 2/- each, for the Financial Year 2023-24. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "October 30, 2023" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 09, 2023.
お知らせ • Oct 14Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023Laurus Labs Limited announced that they will report Q2, 2024 results on Oct 20, 2023
お知らせ • Sep 12Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million.Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million on September 11, 2023. Pursuant to the above acquisition, the stake of Laurus Labs in Laurus Bio shall reach to 87.58% on fully diluted basis (including outstanding ESOPs and the Share Warrants). Laurus Bio has revenue of INR 1,286.26 million, EBITDA of INR 369 million, total assets of INR 1,982.54 million, total equity of INR 481.64 million and net income of INR 141.9 million as of March 31, 2023. The Board of Directors of Laurus Labs have accorded its final approval for acquisition.
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹392, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹190 per share.
New Risk • Jul 28New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.9% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Dividend is not well covered by cash flows (dividend per share is over 28x cash flows per share). Profit margins are more than 30% lower than last year (9.9% net profit margin).
Reported Earnings • Jul 28First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023)First quarter 2024 results: EPS: ₹0.46 (down from ₹4.68 in 1Q 2023). Revenue: ₹11.9b (down 23% from 1Q 2023). Net income: ₹248.5m (down 90% from 1Q 2023). Profit margin: 2.1% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Jun 24Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹14.69 (down from ₹15.42 in FY 2022). Revenue: ₹60.4b (up 22% from FY 2022). Net income: ₹7.90b (down 4.5% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 39 Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jun 01Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million.Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million on May 31, 2023. Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86%. In related transaction some of the Promoters and senior management of Laurus Labs would also invest approximately INR 40 million to purchase 0.54% stake. Transaction is expected to complete in approximately one month.
Upcoming Dividend • May 03Upcoming dividend of ₹1.20 per share at 0.6% yieldEligible shareholders must have bought the stock before 10 May 2023. Payment date: 27 May 2023. Payout ratio is a comfortable 14% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).
Price Target Changed • Apr 30Price target decreased by 11% to ₹382Down from ₹430, the current price target is an average from 10 analysts. New target price is 24% above last closing price of ₹308. Stock is down 47% over the past year. The company is forecast to post earnings per share of ₹12.56 for next year compared to ₹14.69 last year.
Reported Earnings • Apr 28Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: ₹14.69 (down from ₹15.42 in FY 2022). Revenue: ₹60.5b (up 23% from FY 2022). Net income: ₹7.90b (down 4.5% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Feb 01Price target decreased by 10% to ₹470Down from ₹523, the current price target is an average from 11 analysts. New target price is 40% above last closing price of ₹335. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹17.01 for next year compared to ₹15.42 last year.
Reported Earnings • Jan 31Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: EPS: ₹3.78 (up from ₹2.87 in 3Q 2022). Revenue: ₹15.4b (up 50% from 3Q 2022). Net income: ₹2.03b (up 32% from 3Q 2022). Profit margin: 13% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.4%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 22Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023Laurus Labs Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Jan 30, 2023
お知らせ • Nov 25Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private LimitedLaurus Labs Limited announced that it has entered into a security purchase agreement for the issuance of 740,000 equity shares at a price of INR 52.70 per share for gross proceeds INR 38,998,000 on November 23, 2022. The transaction will include participation from Ethan Energy India Private Limited.
Price Target Changed • Nov 16Price target decreased to ₹561Down from ₹619, the current price target is an average from 11 analysts. New target price is 22% above last closing price of ₹462. Stock is down 4.7% over the past year. The company is forecast to post earnings per share of ₹19.27 for next year compared to ₹15.42 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Head of Quality & Executive Director Lakshmana Rao Chunduru was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Oct 28Consensus EPS estimates fall by 14%The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ₹68.3b to ₹63.9b. EPS estimate also fell from ₹22.34 per share to ₹19.27 per share. Net income forecast to grow 31% next year vs 32% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹619 to ₹561. Share price fell 8.8% to ₹445 over the past week.
Upcoming Dividend • Oct 27Upcoming dividend of ₹0.80 per shareEligible shareholders must have bought the stock before 03 November 2022. Payment date: 20 November 2022. Payout ratio is a comfortable 12% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%).
Price Target Changed • Oct 26Price target decreased to ₹574Down from ₹619, the current price target is an average from 11 analysts. New target price is 27% above last closing price of ₹453. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₹19.34 for next year compared to ₹15.42 last year.
お知らせ • Oct 22Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022The board of directors of Laurus Labs Limited in their meeting held on October 21, 2022 have approved for the payment of interim dividend of INR 0.80 (40%) per equity share of INR 2 each, for the financial year 2022-2023. The company has fixed November 04, 2022 as record date for determining the eligibility of the Shareholders. The dividend amount will be paid on or after November 15, 2022.
Reported Earnings • Oct 22Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: ₹4.33 (up from ₹3.76 in 2Q 2022). Revenue: ₹15.8b (up 31% from 2Q 2022). Net income: ₹2.33b (up 15% from 2Q 2022). Profit margin: 15% (down from 17% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 14Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022Laurus Labs Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Oct 21, 2022
Reported Earnings • Jul 28First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: EPS: ₹4.68 (up from ₹4.50 in 1Q 2022). Revenue: ₹15.4b (up 20% from 1Q 2022). Net income: ₹2.51b (up 4.1% from 1Q 2022). Profit margin: 16% (down from 19% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 8.4%. Over the next year, revenue is forecast to grow 33%, compared to a 12% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 20Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022Laurus Labs Limited announced that they will report Q1, 2023 results on Jul 27, 2022
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹444, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹298 per share.
Reported Earnings • Jun 09Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: EPS: ₹15.42 (down from ₹18.36 in FY 2021). Revenue: ₹49.4b (up 2.5% from FY 2021). Net income: ₹8.28b (down 16% from FY 2021). Profit margin: 17% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 34 Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 34%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • May 03Upcoming dividend of ₹1.20 per shareEligible shareholders must have bought the stock before 10 May 2022. Payment date: 28 May 2022. Payout ratio is a comfortable 13% but the company is paying out more than the cash it is generating. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%).
Reported Earnings • Apr 29Full year 2022 earnings: Revenues and EPS in line with analyst expectationsFull year 2022 results: EPS: ₹15.42 (down from ₹18.36 in FY 2021). Revenue: ₹49.5b (up 2.9% from FY 2021). Net income: ₹8.28b (down 16% from FY 2021). Profit margin: 17% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 23%, compared to a 12% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 94% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Executive Director Lakshmana Rao Chunduru was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 22Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022Laurus Labs Limited announced that they will report Q4, 2022 results on Apr 28, 2022
Major Estimate Revision • Feb 03Consensus revenue estimates fall by 14%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from ₹55.7b to ₹47.9b. EPS estimate fell from ₹19.51 to ₹15.40 per share. Net income forecast to grow 18% next year vs 21% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹607 to ₹563. Share price rose 11% to ₹526 over the past week.
Price Target Changed • Feb 02Price target decreased to ₹563Down from ₹607, the current price target is an average from 11 analysts. New target price is 7.1% above last closing price of ₹526. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹15.40 for next year compared to ₹18.36 last year.
Reported Earnings • Jan 28Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: EPS: ₹2.87 (down from ₹5.09 in 3Q 2021). Revenue: ₹10.3b (down 20% from 3Q 2021). Net income: ₹1.54b (down 44% from 3Q 2021). Profit margin: 15% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 37%. Over the next year, revenue is forecast to grow 30%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Nov 10Upcoming dividend of ₹0.80 per shareEligible shareholders must have bought the stock before 17 November 2021. Payment date: 27 November 2021. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.8%).
Reported Earnings • Nov 01Second quarter 2022 earnings released: EPS ₹3.76 (vs ₹4.53 in 2Q 2021)The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹12.0b (up 5.7% from 2Q 2021). Net income: ₹2.02b (down 17% from 2Q 2021). Profit margin: 17% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 22Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹537, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 696% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹557 per share.
Recent Insider Transactions • Sep 22Insider recently sold ₹7.9m worth of stockOn the 17th of September, Vijaya Suryadevara sold around 12k shares on-market at roughly ₹658 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹99m. Insiders have been net sellers, collectively disposing of ₹970m more than they bought in the last 12 months.
Recent Insider Transactions • Sep 11Insider recently sold ₹3.2m worth of stockOn the 6th of September, Sreelakshmi Gogireddy sold around 5k shares on-market at roughly ₹649 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹99m. Insiders have been net sellers, collectively disposing of ₹959m more than they bought in the last 12 months.
Recent Insider Transactions • Sep 04Insider recently sold ₹3.6m worth of stockOn the 31st of August, Yalamanchili Rama sold around 6k shares on-market at roughly ₹657 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹250m. Insiders have been net sellers, collectively disposing of ₹858m more than they bought in the last 12 months.
Recent Insider Transactions • Aug 13Insider recently sold ₹1.0m worth of stockOn the 9th of August, Madhuveer Yadavalli sold around 1k shares on-market at roughly ₹701 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹250m. Insiders have been net sellers, collectively disposing of ₹788m more than they bought in the last 12 months.
Price Target Changed • Aug 04Price target increased to ₹561Up from ₹512, the current price target is an average from 8 analysts. New target price is 13% below last closing price of ₹646. Stock is up 214% over the past year.
Reported Earnings • Jul 30First quarter 2022 earnings released: EPS ₹4.50 (vs ₹3.21 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹12.8b (up 32% from 1Q 2021). Net income: ₹2.41b (up 41% from 1Q 2021). Profit margin: 19% (up from 18% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year whereas the company’s share price has increased by 90% per year.
Price Target Changed • Jul 12Price target increased to ₹506Up from ₹470, the current price target is an average from 8 analysts. New target price is 25% below last closing price of ₹677. Stock is up 443% over the past year.
お知らせ • Jul 03Laurus Labs Limited Receives the License to Manufacture and Market 2-Deoxy-D-Glucose (2DG) in IndiaLaurus Labs Limited announces that it has received the license from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country. Laurus Labs has already applied with CDSCO for emergency use authorization (EUA) for 2DG.
Reported Earnings • Jun 24Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹48.1b (up 70% from FY 2020). Net income: ₹9.84b (up 285% from FY 2020). Profit margin: 20% (up from 9.0% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Pre-registration: 18 Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 90% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • May 23Insider recently bought ₹4.0m worth of stockOn the 21st of May, Satish Adewar bought around 8k shares on-market at roughly ₹486 per share. In the last 3 months, they made an even bigger purchase worth ₹6.4m. Insiders have collectively bought ₹92m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • May 07Insider recently sold ₹35m worth of stockOn the 3rd of May, K. Rao sold around 76k shares on-market at roughly ₹466 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹104m more than they sold in the last 12 months.
Major Estimate Revision • May 06Consensus EPS estimates increase to ₹21.57The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from ₹53.6b to ₹57.9b. EPS estimate increased from ₹19.60 to ₹21.57 per share. Net income forecast to grow 18% next year vs 20% growth forecast for Pharmaceuticals industry in India. Consensus price target up from ₹399 to ₹457. Share price rose 5.1% to ₹482 over the past week.
Price Target Changed • May 05Price target increased to ₹430Up from ₹396, the current price target is an average from 7 analysts. New target price is 13% below last closing price of ₹491. Stock is up 386% over the past year.
Upcoming Dividend • May 04Upcoming dividend of ₹0.80 per shareEligible shareholders must have bought the stock before 11 May 2021. Payment date: 29 May 2021. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.7%).
Reported Earnings • May 01Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹48.4b (up 71% from FY 2020). Net income: ₹9.84b (up 285% from FY 2020). Profit margin: 20% (up from 9.0% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 65% per year, which means it is significantly lagging earnings growth.
